Hikal Limited (NSE:HIKAL)
343.25
-8.80 (-2.50%)
Jul 18, 2025, 3:30 PM IST
Hikal Revenue
In the fiscal year ending March 31, 2025, Hikal had annual revenue of 18.60B INR with 4.21% growth. Hikal had revenue of 5.52B in the quarter ending March 31, 2025, with 7.45% growth.
Revenue
18.60B
Revenue Growth
+4.21%
P/S Ratio
2.34
Revenue / Employee
9.02M
Employees
2,061
Market Cap
43.53B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 18.60B | 752.00M | 4.21% |
Mar 31, 2024 | 17.85B | -2.38B | -11.79% |
Mar 31, 2023 | 20.23B | 803.09M | 4.13% |
Mar 31, 2022 | 19.43B | 2.22B | 12.92% |
Mar 31, 2021 | 17.20B | 2.13B | 14.14% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 525.78B |
Divi's Laboratories | 93.60B |
Cipla | 272.67B |
Mankind Pharma | 122.07B |
Apollo Hospitals Enterprise | 217.94B |
Zydus Lifesciences | 232.42B |
Aurobindo Pharma | 317.24B |
Glenmark Pharmaceuticals | 134.35B |
Hikal News
- 4 weeks ago - Hikal successfully clears ANVISA GMP audit for Bengaluru API manufacturing facility - Business Upturn
- 2 months ago - Hikal receives OAI classification from US FDA for Jigani facility - Business Upturn
- 2 months ago - Hikal share price jumps 4% as Q4 revenue rises 7.4% YoY to Rs 552 crore, net profit up 48% YoY - Business Upturn
- 2 months ago - Hikal Q4 Results: Revenue up 7.4% YoY to Rs 552 crore, Net Profit up 48% YoY - Business Upturn
- 5 months ago - Hikal shares drop over 6% after US FDA issues six observations for Jigani facility - Business Upturn
- 5 months ago - Hikal receives 6 observations for Jigani facility from US FDA - Business Upturn